Innovative Therapy Leadership Trevi Therapeutics is advancing a unique opioid receptor-targeting therapy, Haduvio, which is the first investigational drug to show significant reduction in chronic cough for patients with IPF and related conditions, presenting a promising solution for respiratory treatment markets.

Strong Funding Position With $273 million in funding and recent $115 million capital raise, Trevi has substantial financial resources to accelerate the development, clinical trials, and potential commercialization of its novel therapeutic, making it an attractive partner or customer for biotech and pharma suppliers.

Market Development Opportunities Trevi actively engages in major industry events like the J.P. Morgan Healthcare Conference and European Respiratory Society Congress, indicating ongoing efforts to expand visibility, partnerships, and market access within the respiratory and biotech sectors.

Strategic Clinical Focus As a clinical-stage company specializing in respiratory disorders, Trevi's pipeline and ongoing research present opportunities to collaborate with suppliers of clinical trial services, lab equipment, or respiratory treatment solutions to support its development programs.

Targeted Customer Proposition Given its focus on chronic cough and respiratory conditions, Trevi offers potential sales opportunities for companies providing innovative healthcare technology, patient monitoring tools, or opioid receptor modulators, aligning with its strategic efforts to bring advanced therapeutics to market.